Send to

Choose Destination
J Clin Apher. 2013 Aug;28(4):321-4. doi: 10.1002/jca.21254. Epub 2013 Mar 1.

Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.

Author information

Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.


Immune thrombocytopenic purpura (ITP) is an autoimmune disease in which IgG-coated platelets are removed from circulation by the spleen, and platelet production is impaired due to increased thrombopoietin (TPO) clearance. Romiplostim, a novel TPO-mimetic agent, is approved for patients with ITP that are unresponsive to traditional treatments. However, there is little experience when using this drug before splenectomy. We describe herein the case of a young female with chronic ITP who was treated with romiplostim, underwent splenectomy shortly thereafter, and required plateletpheresis for postoperative rebound thrombocytosis with concomitant neurologic symptoms.


ITP; immune thrombocytopenic purpura; plateletpheresis; romiplostim; splenectomy

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center